
Topic
Community Oncology
Podcasts
Tumor Board # 92Nov 17, 2026Multidisciplinary Approaches in Pancreatic Cancer Care

At Cedars-Sinai, the time from a pancreatic cancer diagnosis to the first dose of chemotherapy fell from about a month to 14 days, and trial enrollment nearly tripled, once every specialist started seeing the patient in the same room on the same day. On this episode of the BackTable GI Oncology Creator Weekend™, medical oncologist Dr. Andrew Hendifar of Cedars-Sinai is joined by surgical oncologist Dr. Adam Yopp, chief of surgical oncology at UT Southwestern, and GI medical oncologist Dr. Arsen Osipov of Cedars-Sinai to compare how their same-day multidisciplinary clinics run and what every clinic needs, from an experienced pancreatic surgeon and a radiation oncologist to genetic counseling, an early dietitian visit, and supportive care. They also explain how virtual tumor boards, same-week biopsy slots, and outreach networks bring community oncologists in Texas and California into the plan, and weigh whether pancreatic cancer care should be regionalized, as it is in parts of Canada.
Tumor Board # 89Nov 2, 2026Perioperative Management of Pancreatic Cancer

Most patients with localized pancreatic cancer already have disease the scans cannot see, which is why these GI oncologists treat chemotherapy before surgery as a test of tumor biology. On this episode of the BackTable GI Oncology Creator Weekend™, medical oncologist Dr. Andrew Hendifar leads a tumor board with GI medical oncologists Dr. Arsen Osipov and Dr. Daniel Ahn on the perioperative management of pancreatic cancer. They explain why nearly every patient with localized disease now starts with chemotherapy rather than surgery, which red flags such as an elevated CA 19-9, enlarged lymph nodes, or profound weight loss point to hidden micrometastatic disease, and why an 80-year-old can still be a candidate for FOLFIRINOX when biological age outweighs chronological age.
Tumor Board # 86Oct 20, 2026Optimizing Treatment for Advanced HER2-Positive Upper GI Cancers

When a gastroesophageal tumor is positive for HER2, PD-L1, and claudin 18.2, which target should you treat first and how do you decide? On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews Dr. Geoffrey Buckle, a GI medical oncologist at UCSF, and Dr. Ronan Hsieh, a GI oncologist at Swedish Cancer Institute in Seattle, for a breakdown of therapy selection and management in advanced HER2-positive upper GI cancers. They start with a detailed case, covering biomarker workup, how to choose a first-line regimen without head-to-head data, and how to manage nutrition and palliative radiation when a patient presents with dysphagia and weight loss.
Tumor Board # 85Oct 13, 2026Perioperative Management in Upper GI Cancers

How do you choose between perioperative chemotherapy and trimodality therapy for a patient with localized upper GI cancer, and what has the newest data actually settled? On this episode of BackTable Tumor Board, host Dr. Kate Baker interviews Dr. Dani Castillo, a medical oncologist at City of Hope in Duarte, California, and Dr. Alexandra Gangi, a gastrointestinal surgical oncologist at Cedars-Sinai in Los Angeles, about everything that happens between a new diagnosis and a resection in localized esophageal, gastroesophageal junction and gastric cancer. They cover diagnostic workup, Siewert classification, staging laparoscopy, histology, biomarker testing, surgical candidacy, and the challenges of nutrition and prehabilitation.
Tumor Board # 80Sep 8, 2026Scaling Community CAR-T: Operational Lessons & Future Directions

How does delivering CAR-T in the community change patient care, and what has to happen next for these programs to scale? On this episode of the BackTable Tumor Board Podcast, host Aaron Lyss interviews Dr. Mike Byrne, hematologist at Tennessee Oncology and medical director for cellular therapy at OneOncology, about operational lessons and future directions for outpatient CAR-T therapy. They discuss the impact of faster time to treatment, building trust through local relationships, and the weekly pipeline management that keeps the program moving.
Tumor Board # 78Aug 25, 2026Developing CAR T-Cell Programs in Community Oncology

Where does access to cell therapy actually break down, and can community practices close the gap? On this episode of BackTable Tumor Board, host Aaron Lyss interviews Dr. Mike Byrne, a hematologist at Tennessee Oncology, about the challenges and successes of building an outpatient CAR T program in the community setting. They discuss the critical stakeholder relationships, operational and financial structures, and patient pathways that enable a physician-owned practice to offer cellular therapy outside a hospital system.
Industry # 102Jun 16, 2026Community Oncology: Keeping Up with Evolving Treatments in Early Career

The transition between residency or fellowship to clinical practice can be a big jump, especially when it comes to keeping up with new data and independently making decisions with patients. In this episode of BackTable Industry, Anish Parikh hosts medical oncologist Dr. Kate Baker shares her experience managing a broad range of patients, from solid tumors to benign and malignant hematology.